Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozempic for Lean Body Mass Preservation in Elderly Obese Patients
NCT05302596Phase 2Completed
- Sponsor
- University at Buffalo
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in obesity, sponsored by University at Buffalo. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05302596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302596.